Ovarian carcinoma patients with a tumor <i>BRCA</i> -like genomic copy number aberration profile benefit from maintenance olaparib/bevacizumab therapy in the PAOLA-1 randomized controlled trial

Philip C. Schouten, Rita K. Schmutzler|medRxiv|2023

Cited by 0